Article
Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.
European urology oncology - 1 Aug 2021
Karlsson Questa, Brook Mark N, Dadaev Tokhir, Wakerell Sarah, Saunders Edward J, Muir Kenneth, Neal David E, Giles Graham G, MacInnis Robert J, Thibodeau Stephen N, McDonnell Shannon K, Cannon-Albright Lisa, Teixeira Manuel R, Paulo Paula, Cardoso Marta, Huff Chad, Li Donghui, Yao Yu, Scheet Paul, Permuth Jennifer B, Stanford Janet L, Dai James Y, Ostrander Elaine A, Cussenot Olivier, Cancel-Tassin Géraldine, Hoegel Josef, Herkommer Kathleen, Schleutker Johanna, Tammela Teuvo L J, Rathinakannan Venkat, Sipeky Csilla, Wiklund Fredrik, Grönberg Henrik, Aly Markus, Isaacs William B, Dickinson Jo L, FitzGerald Liesel M, Chua Melvin L K, Nguyen-Dumont Tu, Schaid Daniel J, Southey Melissa C, Eeles Rosalind A, Kote-Jarai Zsofia
Abstract excerpt
BACKGROUND: Germline ATM mutations are suggested to contribute to predisposition to prostate cancer (PrCa). Previous studies have had inadequate power to estimate variant effect sizes. OBJECTIVE: To precisely estimate the contribution of germline ATM mutations to PrCa risk. DESIGN, SETTING, AND PARTICIPANTS: We analysed next-generation sequencing data from 13 PRACTICAL study groups comprising 5560 cases and 3353...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
